Please provide your email address to receive an email when new articles are posted on . Patients were more likely to achieve sustained remission with sarilumab vs. placebo. The most common adverse ...
Sarilumab, a biologic, is sold as Kevzara. The FDA recently approved sarilumab (Kevzara) for the treatment of adults with polymyalgia rheumatica (PMR) who had an inadequate response to corticosteroids ...
More than half of patients with polymyalgia rheumatica have a relapse during tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 blockade may be clinically useful in ...
The recent FDA approval of sarilumab for the treatment of refractory polymyalgia rheumatica may have a significant and lasting impact on the use of long-term steroids for that condition. The phase 3, ...
The US Food and Drug Administration (FDA) has approved sarilumab (Kevzara) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) for patients weighing ≥ 63 kg (139 lb).
PARIS – September 1, 2020 – Sanofi today announced that the global Phase 3 trial investigating intravenously administered Kevzara® (sarilumab) at a dose of 200 mg or 400 mg [a] in severely or ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the first patient outside of the U.S. has been treated as part of a global clinical program evaluating Kevzara ® (sarilumab) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results